A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.

Name: Αlpha¹ Rigor Record — A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.
Item: A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.
Rating: 100
Author: Αlpha¹

Adigweme I, Yisa M, Ooko M, Akpalu E, Bruce A, Donkor S, Jarju LB, Danso B, Mendy A, Jeffries D, Segonds-Pichon A, Njie A, Crooke S, El-Badry E, Johnstone H, Royals M, Goodson JL, Prausnitz MR, McAllister DV, Rota PA, Henry S, Clarke E

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.5★ (Adequate), 0 critical, 3 high issues for “A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.5 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

ClaimsUnsupported claim (uncorroborated)−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No reported statistical tests were found to recompute.
No data or code availability links were detected to verify.

Problems surfaced3 types

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions not supported by the paper’s own evidenceAssessed
Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 1/2 clinical trial of a measles-rubella vaccine microneedle patch. The paper demonstrates strong scientific premise, rigorous design, clear ethical approvals, and appropriate descriptive statistical analysis. Minor reporting gaps (outlier handling, explicit reporting guideline, and a few copyedit issues) do not undermine the overall robustness.

Both reviewers independently scored all eight dimensions and agreed on every status; no divergence required reconciliation. The statistics verification component checked 0 tests due to coverage limitations (no test statistics with df or effect estimates with CIs were machine-verifiable), so statistical correctness is not independently confirmed. The citation check found no retracted or unresolved references. The claim audit flagged one unsupported claim about thermostability.

5 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Reporting

Eight Dimensions8 pass

The introduction and 'Research in context' section cite prior studies on microneedle patches for influenza and Japanese encephalitis vaccines, and note the absence of data in children and for MRV. The rationale linking the need for improved vaccine coverage to MNP technology is well articulated. Limitations of prior research (e.g., no pediatric data) are explicitly identified and addressed by this trial.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work cited and a logical rationale for the study.

Evidence

direct quote[Introduction, Research in context]

“Five studies have been conducted in adults examining the administration of the inactivated influenza vaccine by dissolvable (n=2) or solid (n=3) microneedle patches.”